So why is Alexion paying $100M for a PRV as AstraZeneca lines up their $39B buyout?
It looks like AstraZeneca may have a bonus waiting once it’s done acquiring Alexion.
Yesterday, Rhythm Pharmaceuticals put out word that the biotech sold their newly won priority review voucher for $100 million — but without identifying the buyer. And then, after the market close, we found out in an SEC filing that the mystery buyer was Alexion.
Alexion has been scooping up new approvals for its Soliris successor, Ultomiris, with an emergency Phase III underway for Covid-19. But there’s not a lot of new drugs in the late-stage pipeline lining up for a run at a quick OK.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,200+ biopharma pros reading Endpoints daily — and it's free.